TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive In Brief: Evaluation Of Potential Immunoassay Components Sought; Promising Results Could Lead to Contract September 19, 1975
TCL Archive Administration To Hold ASSIST Funding To ’92 Level; ACS Says Result Is Percent Cut March 20, 1992
TCL Archive In Brief: Panel to Meet June 9 In Boston; Iverson Takes Position At U. Colo.’Namovicz Leaving NHLBI May 23, 1986
TCL Archive Risk of Breast Cancer Recurrence Reduced With Letrozole, International Study Finds October 31, 2003
